Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB₂R selective benzimidazoles reveal unexpected intrinsic properties.

Nimczick M, Pemp D, Darras FH, Chen X, Heilmann J, Decker M.

Bioorg Med Chem. 2014 Aug 1;22(15):3938-46. doi: 10.1016/j.bmc.2014.06.008. Epub 2014 Jun 13.

PMID:
24984935
2.

5-Sulfonyl-benzimidazoles as selective CB2 agonists.

Verbist BM, De Cleyn MA, Surkyn M, Fraiponts E, Aerssens J, Nijsen MJ, Gijsen HJ.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2574-9. doi: 10.1016/j.bmcl.2008.03.048. Epub 2008 Mar 20.

PMID:
18394887
3.

Design, synthesis, biological evaluation and binding mode modeling of benzimidazole derivatives targeting the cannabinoid receptor type 1.

Espinosa-Bustos C, Lagos CF, Romero-Parra J, Zárate AM, Mella-Raipán J, Pessoa-Mahana H, Recabarren-Gajardo G, Iturriaga-Vásquez P, Tapia RA, Pessoa-Mahana CD.

Arch Pharm (Weinheim). 2015 Feb;348(2):81-8. doi: 10.1002/ardp.201400201. Epub 2015 Jan 13.

PMID:
25641513
4.

Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure.

Huang G, Pemp D, Stadtmüller P, Nimczick M, Heilmann J, Decker M.

Bioorg Med Chem Lett. 2014 Sep 1;24(17):4209-14. doi: 10.1016/j.bmcl.2014.07.038. Epub 2014 Jul 19.

PMID:
25096297
5.

Optimisation of a novel series of selective CNS penetrant CB(2) agonists.

Watson C, Owen DR, Harding D, Kon-I K, Lewis ML, Mason HJ, Matsumizu M, Mukaiyama T, Rodriguez-Lens M, Shima A, Takeuchi M, Tran I, Young T.

Bioorg Med Chem Lett. 2011 Jul 15;21(14):4284-7. doi: 10.1016/j.bmcl.2011.05.063. Epub 2011 May 25.

PMID:
21669533
6.

7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.

Rempel V, Volz N, Hinz S, Karcz T, Meliciani I, Nieger M, Wenzel W, Bräse S, Müller CE.

J Med Chem. 2012 Sep 27;55(18):7967-77. Epub 2012 Sep 11.

PMID:
22916707
7.

Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.

Zhang Y, Gilliam A, Maitra R, Damaj MI, Tajuba JM, Seltzman HH, Thomas BF.

J Med Chem. 2010 Oct 14;53(19):7048-60. doi: 10.1021/jm1006676.

8.
9.

Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.

Behrenswerth A, Volz N, Toräng J, Hinz S, Bräse S, Müller CE.

Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. doi: 10.1016/j.bmc.2009.02.027. Epub 2009 Feb 21.

PMID:
19278853
10.

Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.

Franks LN, Ford BM, Madadi NR, Penthala NR, Crooks PA, Prather PL.

Eur J Pharmacol. 2014 Aug 15;737:140-8. doi: 10.1016/j.ejphar.2014.05.007. Epub 2014 May 20.

11.

Protocol to Study β-Arrestin Recruitment by CB1 and CB2 Cannabinoid Receptors.

Soethoudt M, van Gils N, van der Stelt M, Heitman LH.

Methods Mol Biol. 2016;1412:103-11. doi: 10.1007/978-1-4939-3539-0_11.

PMID:
27245896
12.

Synthesis and biological evaluation of (3',5'-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist.

Presley CS, Mustafa SM, Abidi AH, Moore BM 2nd.

Bioorg Med Chem. 2015 Sep 1;23(17):5390-401. doi: 10.1016/j.bmc.2015.07.057. Epub 2015 Jul 29.

PMID:
26275680
13.

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA.

Pharmacol Rev. 2010 Dec;62(4):588-631. doi: 10.1124/pr.110.003004. Review.

14.

Selective CB2 receptor agonists. Part 1: the identification of novel ligands through computer-aided drug design (CADD) approaches.

Hickey ER, Zindell R, Cirillo PF, Wu L, Ermann M, Berry AK, Thomson DS, Albrecht C, Gemkow MJ, Riether D.

Bioorg Med Chem Lett. 2015 Feb 1;25(3):575-80. doi: 10.1016/j.bmcl.2014.12.033. Epub 2014 Dec 17.

PMID:
25556098
15.

1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.

Hou DR, Alam S, Kuan TC, Ramanathan M, Lin TP, Hung MS.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):1022-5. doi: 10.1016/j.bmcl.2008.11.029. Epub 2008 Nov 14.

PMID:
19095444
16.

Endocannabinoids and Their Pharmacological Actions.

Pertwee RG.

Handb Exp Pharmacol. 2015;231:1-37. doi: 10.1007/978-3-319-20825-1_1. Review.

PMID:
26408156
17.

Identification of CB1/CB2 ligands from Zanthoxylum bungeanum.

Dossou KS, Devkota KP, Morton C, Egan JM, Lu G, Beutler JA, Moaddel R.

J Nat Prod. 2013 Nov 22;76(11):2060-4. doi: 10.1021/np400478c. Epub 2013 Oct 31.

PMID:
24175626
18.

Benzimidazole CB2 agonists: design, synthesis and SAR.

Nanda KK, Henze DA, Della Penna K, Desai R, Leitl M, Lemaire W, White RB, Yeh S, Brouillette JN, Hartman GD, Bilodeau MT, Trotter BW.

Bioorg Med Chem Lett. 2014 Feb 15;24(4):1218-21. doi: 10.1016/j.bmcl.2013.12.068. Epub 2013 Dec 25.

PMID:
24461289
19.

Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.

Han S, Zhang FF, Qian HY, Chen LL, Pu JB, Xie X, Chen JZ.

Eur J Med Chem. 2015 Mar 26;93:16-32. doi: 10.1016/j.ejmech.2015.01.054. Epub 2015 Jan 26.

PMID:
25644673
20.

Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.

Svízenská I, Dubový P, Sulcová A.

Pharmacol Biochem Behav. 2008 Oct;90(4):501-11. doi: 10.1016/j.pbb.2008.05.010. Review.

PMID:
18584858

Supplemental Content

Support Center